Epidemiology of primary focal dystonias in the western area of Tottori Prefecture in Japan: Comparison with prevalence evaluated in 1993
Epidemiology of primary focal dystonias in the western area of Tottori Prefecture in Japan: Comparison with prevalence evaluated in 1993
复制标题
DOI：
10.1002/mds.20986
复制
发表时间：
2006-09-01
影响因子：
8.6
通讯作者：
Nakashima, Kenji
中科院分区：
文献类型：
--
作者：
Fukuda, Hiroki;Kusumi, Masayoshi;Nakashima, Kenji
2003年在日本鸟取县西部地区进行了原发性局灶性肌张力障碍流行病学调查，并将结果与1993年的调查结果进行了比较。原发性局灶性肌张力障碍的服务患病率为每10万人13.7例，较1993年调查有所上升。 1997 年，A 型肉毒杆菌毒素在日本被批准用于治疗眼睑痉挛，目前在日本各地的医疗中心接受评估和诊断患有局灶性肌张力障碍的患者数量的增加可能是导致患病率增加的原因。每 10 万人中按亚型划分的患病率如下：面部肌张力障碍，6.5；痉挛性斜颈，2.0；作家痉挛，4.4；和其他局灶性肌张力障碍； 0.8。在这些亚型中，面部肌张力障碍的患病率增加最为显着。 (c) 2006 年运动障碍协会。
An epidemiological survey of primary focal dystonias in the western area of Tottori Prefecture in Japan was conducted in 2003, and the results were compared with those of a previous survey in 1993. The service-based prevalence of primary focal dystonia was 13.7 per 100,000 population, representing an increase from that found in the 1993 survey. In 1997, botulinum toxin type A was approved for use in Japan to treat blepharospasm, and the increased number of patients now being evaluated and diagnosed with focal dystonias at medical centers throughout Japan may be responsible for this increased prevalence. Prevalence by subtype per 100,000 population was as follows: facial dystonia, 6.5; spasmodic torticollis, 2.0; writer's cramp, 4.4; and other focal dystonias; 0.8. Facial dystonia showed the most marked increase in service-based prevalence among these subtypes. (c) 2006 Movement Disorder Society.